Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LPO | P22079 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631379 | 0.87 | ALDH1A1 (0.40) | PRKCIBRPF1NTSR1CHEK1AURKA | |
| SCHEMBL7483288 | 0.84 | PRKCI (0.47) | PRKCIBRPF1NTSR1CHEK1AURKA | |
| SCHEMBL312329 | 0.83 | PIK3CD (0.51) | PRKCIBRPF1NTSR1CHEK1AURKA | |
| SCHEMBL4175475 | 0.82 | TFPI2 (0.48) | TUBB1NOTUMTFPI2MAPTCYP11B1 | |
| SCHEMBL853076 | 0.81 | NOTUM (0.58) | PRKCIBRPF1NTSR1CHEK1AURKA | |
| SCHEMBL7988808 | 0.81 | TUBB1 (0.60) | TUBB1TFPI2ALDH1A1 | |
| SCHEMBL5101602 | 0.81 | PRKCI (0.50) | PRKCIBRPF1NTSR1CHEK1AURKA | |
| SCHEMBL6022262 | 0.81 | TUBB1 (0.44) | NTSR1TUBB1NOTUMLPOTFPI2 | |
| SCHEMBL4959132 | 0.80 | PRKCI (0.52) | PRKCIBRPF1NTSR1CHEK1AURKA | |
| SCHEMBL13598508 | 0.80 | PRKCI (0.52) | PRKCIBRPF1NTSR1CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| CN-1723022-A | inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 | STERIX LTD (GB) | 2006-01-18 | — | — | CN | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | PRKCI 1284/4885BRPF1 3515/4885NTSR1 769/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | PRKCI 4292/4885BRPF1 2206/4885NTSR1 156/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | PRKCI 4292/4885BRPF1 2206/4885NTSR1 156/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | PRKCI 4627/4885BRPF1 3385/4885NTSR1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.